Avacta Group Vlastní kapitál 2024

Co dělá Avacta Group?

Avacta Group PLC is a British company specializing in the development of innovative solutions for biotechnology and diagnostics. It was founded in 2004 by Eliot Forster and is headquartered in Wetherby, West Yorkshire. Avacta's history began with the development of Affimer technology, which offers an alternative to conventional antibodies. Affimers are synthetic peptides with high binding affinity to biological molecules, making them important tools for biomedical research and diagnostic applications. The company had limited resources in its early years, and it took several years to complete the development of Affimer technology. In recent years, Avacta has expanded its business model by offering licensed services to pharmaceutical companies. The company provides innovative screening methods and drug discovery tools based on Affimer technology. Avacta has partnerships with major companies such as LG Chem, Moderna, and Wockhardt. The partnership with LG Chem aims to use the platform technology for the development of Covid-19 therapeutics, while the collaboration with Wockhardt focuses on the creation of diagnostic kits and test systems. Avacta's main business areas are biotechnology and diagnostics. The biotechnology division offers screening services for pharmaceutical companies, with a focus on developing higher quality and more efficient antibodies using Affimers, which potentially provide better screening results than traditional antibodies. In the field of diagnostics, the company is working on the development of diagnostic test systems for disease diagnosis. Avacta has started developing diagnostic test kits for Covid-19 that can be used in a laboratory or at home. The company also has a partnership with Adeptrix, a diagnostic tool manufacturing company. Another important area of Avacta is therapeutic applications. Avacta's Affimer technology has already led to new clinical approaches in the development of cancer therapies. Avacta also has a pipeline program of Affimer therapeutics targeting various diseases, from cancer to inflammatory and neurodegenerative diseases. Avacta's products include licensed services for pharmaceutical companies, research kits for Affimer technology, and its own portfolio of Affimer products for various applications in research and diagnostics. The products are exported worldwide, and the company has offices in the United States and South Korea. Overall, Avacta Group PLC has become a major player in the biotechnology and diagnostics industry by expanding its Affimer technology to various applications. Partnerships with major pharmaceutical companies and the development of diagnostic test systems for Covid-19 have brought the company into the public eye and contribute to strengthening its position as a leading provider of Affimer technology in the industry. Avacta Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.